Post Profile






CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity

Cancer cells exploit the expression of the programmed death-1 (PD-1) ligand 1 (PD-L1) to subvert T-cell-mediated immunosurveillance. The success of therapies that disrupt PD-L1-mediated tumour tolerance has highlighted the need to understand the molecular regulation of PD-L1 expression. Here we identify the uncharacterized protein CMTM6 as a critical regulator of PD-L1 in a broad range of cancer cells, by using a genome-wide CRISPR–Cas9 screen.
read more

share

Related Posts


Cell maps reveal fresh details on how the immune system fights cancer

Academics : Nature

Immune cells that encompass and invade tumours could dictate the success or failure of therapy.

Cancer immunotherapy: Drug success factor found

Academics : Nature

The success of a cancer therapy that unleashes immune cells on tumours depends on the cells producing a protein called CD28. The molecule could serve as a biomarker for selecting individuals who are likely to respond to certain immu...

Cancer: Precision T-cell therapy targets tumours

Academics : Nature AOP

The T cells of the immune system can destroy tumours, but their activation can be inefficient. Vaccines that exploit tumour mutations elicit robust T-cell responses to tumours, with potential clinical benefits.

SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin

Academics : Nature AOP

Cancer cells elude anti-tumour immunity through multiple mechanisms, including upregulated expression of ligands for inhibitory immune checkpoint receptors. Phagocytosis by macrophages plays a critical role in cancer control. Therap...

PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity

Academics : Nature AOP

Programmed cell death protein 1 (PD-1) is an immune checkpoint receptor that is upregulated on activated T cells for the induction of immune tolerance. Tumour cells frequently overexpress the ligand for PD-1, programmed cell death l...

Comments


Copyright © 2016 Regator, LLC